Average Co-Inventor Count = 3.91
ph-index = 6
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Biomarin Pharmaceutical Inc. (9 from 135 patents)
2. Leading Biosciences, Inc. (3 from 6 patents)
3. January Therapeutics, Inc. (2 from 2 patents)
4. Zacharon Pharmaceuticals, Inc. (1 from 2 patents)
15 patents:
1. 11306399 - Nanoparticle compositions
2. 11306111 - Organophosphate derivatives
3. 11123317 - Compositions for the treatment of autodigestion
4. 10793894 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition
5. 10677786 - Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
6. 10260084 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition
7. 9915649 - Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVA
8. 9775821 - Compositions for the treatment of autodigestion
9. 9677116 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition
10. 9340822 - Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
11. 9314442 - Compositions for the treatment of autodigestion
12. 9222120 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition
13. 8809009 - Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
14. 8771974 - Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorder
15. 8232073 - Quantification of non-reducing end glycan residual compounds